Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu Jupiter Neurosciences, Inc. - Common Stock
Kein Kurs
28.04.2026 22:04
Aktuelle Kurse von Jupiter Neurosciences, Inc. - Common Stock
Börse
Ticker
Währung
Letzter Umsatz
Kurs
Tagesveränderung
NASDAQ
JUNS
USD
28.04.2026 22:04
0,36 USD
-0,003 USD
-0,72 %
IEX
JUNS
USD
24.04.2026 15:03
0,39 USD
-
Free Float & Liquidität
Free Float50,52 %
Shares Float18,33 M
Ausstehende Aktien36,28 M
Firmenprofil zu Jupiter Neurosciences, Inc. - Common Stock Aktie
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
